Can a single, cheap pill combat cardiovascular disease?

Volunteers are being recruited in Ireland, the Netherlands and the UK to participate in a two-year trial of a single 'polypill' designed to prevent heart attack and stroke. The trials are financed in part by the UMPIRE (Use of a multidrug pill in reducing cardiovascular events) project, which has received EUR 3 million under the Health Theme of the Seventh Framework Programme (FP7).

Cardiovascular disease is the leading cause of death worldwide. The UMPIRE project partners are focusing on people who are at risk of cardiovascular disease or who have already had a heart attack or stroke. They hope to establish whether these patients prefer to take a single pill to prevent cardiovascular events, or to stick to their usual routine of taking several pills.

Originally developed in India, the new, low-cost, one-a-day 'polypill' (also known as the 'Red Heart Pill') contains low-dose aspirin, a statin (a drug that is used to lower blood cholesterol levels) and two blood-pressure-lowering medicines. These drugs are currently prescribed separately to individuals; taken together they can halve the risk of a person having a heart attack or stroke. However, these benefits cannot be realised if patients only take the medication for a short time. At present, many people do not manage to continue taking the pills over the long term.

"The polypill idea is really simple: make it easier for people to get the medication they need by giving them just one polypill to take each day, rather than lots of different pills that may need to be taken at different times," explained Professor Simon Thom of the National Heart and Lung Institute at Imperial College London in the UK.

UMPIRE researchers will also explore whether the single-pill strategy actually reduces blood pressure and lowers cholesterol, and whether it diminishes the likelihood of patients experiencing further cardiovascular events. The results of the European trials will be combined with parallel trials being carried out in Australia and New Zealand as well as further trials awaiting approval in Brazil, Canada, China, India and South Africa. The final data will represent 7,000 patients in 10 countries.

"It's likely that combining medications in one polypill could enable people in low-income countries to have easy access to cheap preventive medication," Professor Thom stated.

The Red Heart Pill's very low cost makes it an ideal candidate for at-risk patients living in countries where individuals have limited access to healthcare, or lack the means to pay for it. If the trials are successful, the project partners plan to find ways to make the polypill available to people with low incomes in developing countries. The researchers believe that the polypill could represent a cost-effective approach to improving the quality of life of millions of people the world over.

"Polypills are being used successfully to treat other diseases like tuberculosis and HIV (human immunodeficiency virus), but we don't yet know whether they could be effective in those with cardiovascular problems," said Professor Thom. "The UMPIRE trial aims to test whether the polypill does help people take their cardiovascular medicines in the long term and whether there are any unintended problems with this approach."

Approximately 2,000 volunteers are being recruited through clinics at Imperial College Healthcare NHS (National Health Service) Trust; the Royal College of Surgeons in Ireland; University Medical Centre Utrecht, the Netherlands; the George Institute, India; the Centre for Chronic Disease Control in New Delhi, the Public Health Foundation of India; the George Institute for International Health, Sydney, Australia; and Dr Reddy's Laboratories, India.

For further information, please visit:
http://www.georgeinstitute.org/major-collaboration-investigates-four-one-polypill

Copyright ©European Communities, 2010
Neither the Office for Official Publications of the European Communities, nor any person acting on its behalf, is responsible for the use, which might be made of the attached information. The attached information is drawn from the Community R&D Information Service (CORDIS). The CORDIS services are carried on the CORDIS Host in Luxembourg - http://cordis.europa.eu. Access to CORDIS is currently available free-of-charge.

Most Popular Now

AstraZeneca to acquire CinCor Pharma to strengthen…

AstraZeneca has entered into a definitive agreement to acquire CinCor Pharma, Inc. (CinCor), a US-based clinical-stage biopharmaceutical company, focused on developing no...

NextPoint Therapeutics announces $80 million Serie…

NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-l...

Time-restricted eating reshapes gene expression th…

Numerous studies have shown health benefits of time-restricted eating including increase in life span in laboratory studies, making practices like intermittent fasting a ...

Incurable liver disease may prove curable

Research led by Associate Professor Duc Dong, Ph.D., has shown for the first time that the effects of Alagille syndrome, an incurable genetic disorder that affects the li...

Scientists develop a cancer vaccine to simultaneou…

Scientists are harnessing a new way to turn cancer cells into potent, anti-cancer agents. In the latest work from the lab of Khalid Shah, MS, PhD, at Brigham and Women’s ...

Bayer to accelerate drug discovery with Google Clo…

Bayer AG and Google Cloud announced a collaboration to drive early drug discovery that will apply Google Cloud's Tensor Processing Units (TPUs), which are custom-develope...

COVID-19 vaccines, prior infection reduce transmis…

Vaccination and boosting, especially when recent, helped to limit the spread of COVID-19 in California prisons during the first Omicron wave, according to an analysis by ...

Study identifies potential new approach for treati…

Targeting iron metabolism in immune system cells may offer a new approach for treating systemic lupus erythematosus (SLE) - the most common form of the chronic autoimmune...

Nanotechnology may improve gene therapy for blindn…

Using nanotechnology that enabled mRNA-based COVID-19 vaccines, a new approach to gene therapy may improve how physicians treat inherited forms of blindness. A collabo...

Acquisition of Neogene Therapeutics completed

AstraZeneca has completed the acquisition of Neogene Therapeutics Inc. (Neogene), a global clinical-stage biotechnology company pioneering the discovery, development and ...

Modified CRISPR-based enzymes improve the prospect…

Many genetic diseases are caused by diverse mutations spread across an entire gene, and designing genome editing approaches for each patient’s mutation would be impractic...

Pfizer expands 'An Accord for a Healthier World' p…

Pfizer Inc. (NYSE: PFE) announced that it has significantly expanded its commitment to An Accord for a Healthier World to offer the full portfolio of medicines and vaccin...